BMC’s Post

Last year there was a huge medical breakthrough led by Dr. Georg Schett, developing CAR-T Therapies for SLE patients, reporting complete medication-free remission of systemic lupus erythematosus (SLE) lasting up to a year in five patients. A new discovery emerges from the labs at Mayo Clinic. By fusing the power of chimeric antigen receptors (CAR) with the versatility of mesenchymal stromal cells (MSC), they've engineered 'CAR-MSCs'.MSCs are already known as immune system pacifiers, safe for many disorders. Yet, standard MSC treatments have hit a wall with inconsistent results. The breakthrough illustrates how CAR-MSCs hone in on inflamed tissues, delivering a more controlled and potent immunosuppressant action. These engineered cells mark a shift towards greater efficacy and precision in managing graft-versus-host disease, ulcerative colitis Crohn's disease and other inflammatory autoimmune disorders. Can Dr. Saad Kenderian and his team at the Mayo Clinic replicate FAU's success? #CARMSCs #Inflammation #AutoimmuneDisease #Immunotherapy #CART #Immunosuppression #SLE #CrohnsDisease #Gvhd

Had a nice call with Heather Stombaugh, MBA this morning who reminded me of an aricle I was sent yesterday in my #jdrf Insider News email. This JDRF funded study recently published in the #nejm showing the importance of cell signaling pathway(s) in the progression in patients developing #t1d. Treatment of those patients with #baricitinib (a JAK inhibitor, where Janus Kinase is important in cell signaling, growth and survival) showed no significant decrease in C-peptide levels during the study, which is a well established marker of endogenous insulin production. This is another study showing significant results in preserving pancreatic beta-cell function. Baricitinib is known to and used to treat a number of #autoimmunedisease and chronic inflammatory disorders and also is crucial in downregulating cell signaling pathways involved in immune regulation and inflammatory response. This is another important piece in looking at specific mechanisms of decreasing immune response in autoimmune disease but also looking at specific cell signaling pathways to preserve beta-cell function. This important work being funded by #jdrf is another valuable piece into disease modification for those already living with Type 1 diabetes while additional work looks for prevention prior to diagnosis.

📚 Exciting News: Publication in Diabetic Kidney Disease Treatment! 🌟 This paper explored a new way to help people with Diabetic Kidney disease! Our kidneys work like filters in a car engine, but unlike cars, you can't just take a person to the mechanic for an oil change and a new filter! The challenge is to fix the kidney while it's still working. In a recent study (https://lnkd.in/eWFHu6_q), a ground breaking approach was explored, using special cells from the bone marrow to improve kidney function in people with Diabetic Kidney Disease. These cells are called allogeneic mesenchymal stromal stem cells (MSCs), and they have the potential to fix what's gone wrong in diabetic kidney disease. The study showed promising results - the MSCs were safe for the patients and improved kidney function in two out of three measures. Even though the study had a limited number of participants due to COVID-19 challenges, it's a step in the right direction and brings hope for new treatments for those with diabetic kidney disease. Let's keep our fingers crossed for further developments in this area! 🧬🩺 #MedicalAdvancements #KidneyHealth #DiabetesAwareness #diabetes For more information, go to https://lnkd.in/eeEPHGwq

🔬 In a recent study publish earlier this year, Hasegawa and his colleagues have developed an immunoassay to measure the levels of a key chemokine, CXCL9, linked to type 1 inflammation. 🧪 The immunoassay demonstrated excellent precision, sensitivity, and linearity, making it a valuable tool for assessing inflammatory conditions. It also showed low cross-reactivity with other chemokines and compounds, ensuring accurate measurements. 💡 The study found that serum CXCL9 levels were elevated in patients with asthma, interstitial lung diseases, and even COVID-19 infection. This suggests that CXCL9 could serve as a biomarker for type 1 inflammation, helping in the diagnosis and monitoring of these conditions. 🌟 Understanding the role of CXCL9 in inflammatory pathophysiology opens up new possibilities for targeted treatments and personalized medicine approaches. 👩⚕️👨⚕️ These findings have the potential to revolutionize clinical practice by providing clinicians with a reliable tool to assess type 1 inflammation in patients with acute or chronic diseases. 🔗 Read more here https://lnkd.in/egJfR9PD #immunology #research #inflammatorydiseases #precisionmedicine #healthcareinnovation

Autoimmunity and autoreactive T cells

In a recent study published in the American Journal of Hematology, it was discovered that #fostamatinib, a promising treatment for warm antibody autoimmune hemolytic anemia (#wAIHA), has the potential to trigger a long-lasting increase in #haemoglobin levels for some #patients. wAIHA is an autoimmune condition where the immune system prematurely destroys healthy #redbloodcells, resulting in #haemolysis. This occurs when the #immunesystem mistakenly targets healthy tissue. In wAIHA and similar autoimmune hemolytic anemias, antibodies "tag" red blood cells, leading to their destruction by other immune cells. As the most prevalent form of autoimmune #hemolyticanemia, wAIHA affects around 1 to 3 individuals out of 100,000 annually and can manifest at any age. https://lnkd.in/dbBSgDKs 🩸 Learn more about wAIHA and other rare anaemias at: https://lnkd.in/drF-_cHg

🔬 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬! Study reveals how TNF-α released by activated T cells drives metabolic reprogramming in rheumatoid arthritis, promoting Akt-mTOR signaling and impacting mitochondrial mass in proinflammatory T cell subsets. Understanding this link sheds light on chronic inflammation mechanisms in autoimmune diseases. #Immunology #Metabolism #RheumatoidArthritis #ResearchDiscovery 🧬 Source:

Biological drugs for inflammatory arthritides have shown positive results, but did you know they can also cause cutaneous immune-related adverse events (irAEs)? Our latest article delves into the clinical features and pathophysiologic mechanisms of these irAEs. It's crucial for physicians to be aware of these events in order to optimize patient outcomes. #immunology #arthritistreatment #biologicaldrugs #medicalresearch